To view this page or post, please Log In Now or
Upgrade with one of the services below:
Discovering tier one quality Microcap stocks and protecting investors from fraud for 13 years
Calls To Action
A future biotech catalyst announcement we believe is not likely to be negative, but supporting data from clinical studies may be inconsistent. Efficient treatment options also may already exist for patients. As a result, the market’s reaction to a positive catalyst could be minimal.
The drug or device typically addresses an unmet medical need with strong data from the company’s clinical studies supporting continued advancement or approval by the FDA. We believe the company or FDA announcement more than likely will be positive.
The drug or device offers a promising therapy for a disease with poor, if any, treatment options. The drug or device has received strong support from key opinion leaders, primarily because of excellent supporting data from clinical studies. We believe the upcoming company or FDA announcement is likely to be positive.